$53.10−0.02 (−0.04%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
MBX Biosciences (MBX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld.
The four lines that matter · FY23–FY25
Revenue ($M)—
0.0
FY23→FY25CAGR —
Net income ($M)▼40.5%
−87.0
FY23→FY25CAGR —
Free cash flow ($M)▼47.4%
−81.9
FY23→FY25CAGR —
Diluted EPS▲59.1%
−2.38
FY23→FY25CAGR —
What the income statement says · FY23–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY23–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7518, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | YoY | CAGR 23→25 |
|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||
Revenue | — | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 101.3 | 79.2 | 57.4 | 28.5 | ▲37.9% | +66.6% |
Selling, general & admin | 59.1 | 18.9 | 10.8 | 6.8 | ▲75.3% | +67.0% |
Total operating expenses | 160.3 | 98.1 | 68.2 | 35.3 | ▲43.8% | +66.6% |
Operating incomefeeds ROC rank | −160.3 | −98.1 | −68.2 | −35.3 | ▼43.8% | — |
Other income, net | 15.2 | 11.1 | 6.3 | 2.7 | — | — |
Pretax income | −145.1 | −87.0 | −61.9 | −32.6 | ▼40.5% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −145.1 | −87.0 | −61.9 | −32.6 | ▼40.5% | — |
| Per share | ||||||
Diluted EPSbuyback-sensitive | −3.03 | −2.38 | −5.82 | −31.96 | ▲59.1% | — |
Diluted shares (mn) | 48.56 | 36.51 | 10.64 | 1.02 | ▲243.0% | +498.6% |
| Margins | ||||||
† TTM = trailing four quarters through 2026-09-30.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

